LU91362I2 - Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) - Google Patents

Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)

Info

Publication number
LU91362I2
LU91362I2 LU91362C LU91362C LU91362I2 LU 91362 I2 LU91362 I2 LU 91362I2 LU 91362 C LU91362 C LU 91362C LU 91362 C LU91362 C LU 91362C LU 91362 I2 LU91362 I2 LU 91362I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
invega
paliperidone
compounds
acceptable derivatives
Prior art date
Application number
LU91362C
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LU91362I2 publication Critical patent/LU91362I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU91362C 1988-11-07 2007-09-12 Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) LU91362I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26785788A 1988-11-07 1988-11-07

Publications (1)

Publication Number Publication Date
LU91362I2 true LU91362I2 (fr) 2007-11-12

Family

ID=23020416

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91362C LU91362I2 (fr) 1988-11-07 2007-09-12 Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)

Country Status (21)

Country Link
EP (1) EP0368388B1 (fr)
JP (1) JP2758045B2 (fr)
KR (1) KR0146053B1 (fr)
AT (1) ATE122349T1 (fr)
AU (1) AU614437B2 (fr)
CA (1) CA2000786C (fr)
CL (1) CL43432B (fr)
CY (2) CY1926A (fr)
DE (2) DE122007000081I2 (fr)
DK (1) DK169923B1 (fr)
ES (1) ES2075036T3 (fr)
FI (1) FI92201C (fr)
HK (1) HK131696A (fr)
IE (1) IE66370B1 (fr)
IL (1) IL92208A0 (fr)
LU (1) LU91362I2 (fr)
NL (1) NL300298I2 (fr)
NO (2) NO173015C (fr)
NZ (1) NZ231062A (fr)
PT (1) PT92206B (fr)
ZA (1) ZA898436B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
AU672182B2 (en) * 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
ES2050069B1 (es) * 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
JP3645906B2 (ja) * 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類
RU2126406C1 (ru) * 1993-11-23 1999-02-20 Жансен Фармасетика Н.В. Эфирные производные 9-гидрокси-пиридо[1,2-а]пиримидин-4-она, способ их получения, композиция, обладающая антипсихотической активностью и способ ее получения
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1999059589A1 (fr) * 1998-05-18 1999-11-25 Sepracor Inc. Compositions d'hydroxyrisperidone (-) et methodes associees
AU3900499A (en) * 1998-05-18 1999-12-06 Sepracor, Inc. (+)-hydroxyrisperidone compositions and methods
AU5489299A (en) 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
ES2197801B1 (es) * 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
AU2003288017A1 (en) 2002-11-13 2004-06-03 Synthon B.V. Process for making risperidone and intermediates therefor
ES2546268T3 (es) 2004-09-09 2015-09-22 Janssen Pharmaceutica Nv Preparación de 9-hidroxi-3-(2-hidroxietil)-2-metil-4H-pirido[1,2-a]pirimidin-4-ona y sus cristales
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP2133352A3 (fr) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Forme cristalline de la 9-hydroxy-rispéridone (palipéridone)
WO2008021342A2 (fr) * 2006-08-14 2008-02-21 Teva Pharmaceutical Industries Ltd. Formes cristallines de la 9-hydroxy-rispéridone (palipéridone)
EP2133351A3 (fr) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Forme cristalline de la 9-hydroxy-rispéridone (palipéridone)
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
KR20090079189A (ko) * 2006-08-23 2009-07-21 테바 파마슈티컬 인더스트리즈 리미티드 Ｃｍｈｔｐ 및 이의 중간체의 합성 방법
US8071767B2 (en) 2007-01-08 2011-12-06 Actavis Group Ptc Ehf Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride
US8314110B2 (en) * 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
WO2009010988A1 (fr) * 2007-07-19 2009-01-22 Natco Pharma Limited Procédé amélioré, industriellement viable pour la préparation de palipéridone de haute pureté
EP2178872A1 (fr) * 2007-07-27 2010-04-28 Synthon B.V. Dérivés de palipéridone
WO2009045489A2 (fr) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Procédé de synthèse de cmhtp, un intermédiaire de la palipéridone
AU2008309411B2 (en) * 2007-10-09 2013-01-31 Cipla Limited Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009074333A1 (fr) * 2007-12-10 2009-06-18 Synthon B.V. Synthèse de palipéridone
NZ586930A (en) * 2008-02-05 2012-06-29 Watson Pharma Private Ltd An improved process for preparation of paliperidone
US20110087024A1 (en) * 2008-04-21 2011-04-14 Glenmark House process for the preparation of paliperidone intermediates
EP2303877B1 (fr) 2008-05-29 2017-02-15 Inke, S.A. Procédé de fabrication de la palipéridone et d'intermédiaires pour celui-ci
WO2010004578A2 (fr) * 2008-06-16 2010-01-14 Msn Laboratories Limited Nouveaux procédés améliorés de préparation de la palipéridone
WO2010003702A1 (fr) * 2008-07-11 2010-01-14 Synthon B.V. Synthèse de palipéridone
US7932385B2 (en) 2008-07-11 2011-04-26 Synthon Bv Paliperidone ketone
SI22856A (sl) * 2008-07-31 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Proces za pripravo paliperidona
EP2161019A1 (fr) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Composition pharmaceutique multi-particules à libération prolongée comportant de la palipéridone
EP2199293A1 (fr) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. Procédé à étape unique pour la préparation de palipéridone en son sel d'oxalate
EP2202234A1 (fr) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification de la palipéridone
ATE544766T1 (de) 2009-07-13 2012-02-15 Krka Verfahren zur synthese von paliperidon
WO2011018246A2 (fr) 2009-08-13 2011-02-17 Synthon B.V. Composition de palipéridone à libération contrôlée
EP2343296A1 (fr) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. Procédé pour la purification de la palipéridone
WO2011074017A1 (fr) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. Nouveau procédé de préparation de palipéridone
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (fr) * 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. Procédé amélioré de préparation de palipéridone très pure
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
CN102153552B (zh) * 2011-03-01 2012-08-22 吉林大学 两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11377445B2 (en) 2018-02-21 2022-07-05 Zenvision Pharma Llp Derivatives of paliperidone and process for the preparation thereof
WO2019246300A1 (fr) 2018-06-19 2019-12-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions, et méthodes de traitement de déficience cognitive
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN116003404A (zh) * 2022-12-14 2023-04-25 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
ES2075036T3 (es) 1995-10-01
NZ231062A (en) 1991-09-25
HK131696A (en) 1996-07-26
NO173015B (no) 1993-07-05
NL300298I1 (nl) 2007-12-03
JP2758045B2 (ja) 1998-05-25
ZA898436B (en) 1991-07-31
EP0368388A2 (fr) 1990-05-16
CA2000786A1 (fr) 1990-05-07
NL300298I2 (nl) 2008-03-03
IL92208A0 (en) 1990-07-26
DK169923B1 (da) 1995-04-03
NO2007017I1 (no) 2008-01-14
JPH02191276A (ja) 1990-07-27
NO2007017I2 (no) 2010-01-25
DE68922577D1 (de) 1995-06-14
AU4443689A (en) 1990-05-10
CL43432B (es) 2005-06-03
CY2007025I1 (el) 2009-11-04
DK551989D0 (da) 1989-11-06
CY1926A (en) 1989-10-30
FI92201C (fi) 1994-10-10
EP0368388A3 (fr) 1991-07-17
IE893564L (en) 1990-05-07
AU614437B2 (en) 1991-08-29
NO894411D0 (no) 1989-11-06
EP0368388B1 (fr) 1995-05-10
CA2000786C (fr) 1999-01-26
PT92206A (pt) 1990-05-31
DE122007000081I2 (de) 2010-01-28
CY2007025I2 (el) 2009-11-04
FI92201B (fi) 1994-06-30
NO894411L (no) 1990-05-08
ATE122349T1 (de) 1995-05-15
DE122007000081I1 (de) 2008-02-28
IE66370B1 (en) 1995-12-27
KR0146053B1 (ko) 1998-08-17
FI895261A0 (fi) 1989-11-06
NO173015C (no) 1993-10-13
DK551989A (da) 1990-05-08
KR910009700A (ko) 1991-06-28
DE68922577T2 (de) 1995-09-28
PT92206B (pt) 1995-07-06

Similar Documents

Publication Publication Date Title
LU91362I2 (fr) Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
FI900085A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
NO176051C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperazinylbenzazol-derivater
AU1810988A (en) Novel n-(4-piperidinyl)bicyclic condensed 2-imidazolamine derivatives
NO176608C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater